Moderna、Pfizer-BioNTech与Janssen新冠疫苗预防成人住院的比较效果
美国CDC等机构在2021年3月11日至8月15日对18州21家医院3689名无免疫抑制的成人住院患者进行病例对照分析,评估三种疫苗预防新冠住院的效果。Moderna疫苗有效率为93%(95%CI 91%-95%),高于Pfizer-BioNTech的88%(95%CI 85%-91%)(p=0.011);两种mRNA疫苗均高于Janssen的71%(95%CI 56%-81%)(均p<0.001)。
要点
- Moderna疫苗预防新冠住院的VE为93%,高于Pfizer-BioNTech的88%(p=0.011)。
- 两种mRNA疫苗VE均高于Janssen疫苗的71%(p<0.001)。
- Pfizer-BioNTech疫苗的保护在接种4个月后下降。
核心结论
- 所有FDA批准或授权的新冠疫苗均对新冠住院提供实质性保护,但不同疫苗的保护水平存在差异。
研究设计与样本
- CDC与合作者在2021年3月11日至8月15日对18州21家医院3689名≥18岁无免疫抑制的住院成人进行病例对照分析。
- 另对100名健康志愿者在完成Moderna、Pfizer-BioNTech或Janssen疫苗全程接种后2-6周比较血清抗刺突IgG和抗RBD IgG水平。
主要发现
- Moderna疫苗预防新冠住院的VE为93%(95%CI 91%-95%),高于Pfizer-BioNTech的88%(95%CI 85%-91%)(p=0.011)。
- 两种mRNA疫苗VE均高于Janssen疫苗的71%(95%CI 56%-81%)(均p<0.001)。
- Pfizer-BioNTech疫苗的保护在接种4个月后下降。
- 接种Janssen疫苗者接种后抗刺突IgG和抗RBD IgG水平显著低于接种Moderna或Pfizer-BioNTech疫苗者。
临床怎么用
- 当前FDA和CDC指南推荐符合条件者接种这三种疫苗中的一种,不偏好特定疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged ≥18 years and aged ≥16 years, respectively. A 1-dose viral vector vaccine (Ad26.COV2 from Janssen [Johnson & Johnson]) received EUA in February 2021 for persons aged ≥18 years (3). The Pfizer-BioNTech vaccine received FDA approval for persons aged ≥16 years on August 23, 2021 (4). Current guidelines from FDA and CDC recommend vaccination of eligible persons with one of these three products, without preference for any specific vaccine (4,5). To assess vaccine effectiveness (VE) of these three products in preventing COVID-19 hospitalization, CDC and collaborators conducted a case-control analysis among 3,689 adults aged ≥18 years who were hospitalized at 21 U.S. hospitals across 18 states during March 11-August 15, 2021. An additional analysis compared serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2, the virus that causes COVID-19, among 100 healthy volunteers enrolled at three hospitals 2-6 weeks after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine. Patients with immunocompromising conditions were excluded. VE against COVID-19 hospitalizations was higher for the Moderna vaccine (93%; 95% confidence interval [CI] = 91%-95%) than for the Pfizer-BioNTech vaccine (88%; 95% CI = 85%-91%) (p = 0.011); VE for both mRNA vaccines was higher than that for the Janssen vaccine (71%; 95% CI = 56%-81%) (all p<0.001). Protection for the Pfizer-BioNTech vaccine declined 4 months after vaccination. Postvaccination anti-spike IgG and anti-RBD IgG levels were significantly lower in persons vaccinated with the Janssen vaccine than the Moderna or Pfizer-BioNTech vaccines. Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.
引用
- Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34555004. doi:10.15585/mmwr.mm7038e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。